GlassScriptPhysician profile
Deanna J Weiser
NPI 1871079541
$1,307.87
in general payments reported to CMS, 2019-2025
30 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $344 · 2023: $275 · 2024: $231 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $710.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $207.10 | 2021-2025 | Evenity, Otezla, Repatha |
| Novo Nordisk INC | $116.10 | 2021-2024 | Rybelsus, Ozempic |
| Pfizer INC. | $88.76 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.49 | 2021-2024 | Jardiance, Tradjenta |
| Lilly USA, LLC | $67.81 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $66.46 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $62.06 | 2021-2025 | Trintellix |
| Dexcom, INC. | $61.39 | 2023-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $53.43 | 2021-2024 | Farxiga |
| Boston Scientific Corporation | $52.25 | 2023-2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $42.55 | 2024-2025 | Camzyos, Eliquis |
| Organon LLC | $36.81 | 2021-2023 | Nexplanon |
| Abbott Laboratories | $35.53 | 2021-2023 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $35.10 | 2022-2023 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $33.99 | 2023-2024 | Gardasil 9, Gardasil, Capvaxive |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $29.71 | 2023 | Uzedy |
| Novartis Pharmaceuticals Corporation | $27.46 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.74 | 2022 | |
| Phathom Pharmaceuticals, INC. | $23.08 | 2024-2025 | Voquezna |
| Kci USA, INC. | $16.69 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.21 | 2025 | Jornay Pm |
| Mimedx Group, INC. | $15.25 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $14.93 | 2025 | Uptravi, Opsumit |
| Medtronic, INC. | $14.51 | 2024 | Minimed 780g |
| Axsome Therapeutics, INC. | $13.85 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.39 | 2023 | Caplyta |
| Biogen, INC. | $12.68 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.65 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.21 | 2021 | |
| Mylan Specialty L.P. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deanna Weiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.